BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 3035025)

  • 1. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria.
    Gomez CM; Richman DP
    J Immunol; 1987 Jul; 139(1):73-6. PubMed ID: 3035025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
    Corey AL; Richman DP; Agius MA; Wollmann RL
    J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.
    Agius MA; Richman DP
    J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding.
    Agius MA; Geannopoulos CJ; Fairclough RH; Richman DP
    J Immunol; 1988 Jan; 140(1):62-8. PubMed ID: 3257231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of myasthenia gravis.
    Hughes BW; Moro De Casillas ML; Kaminski HJ
    Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: clinical and electrophysiological aspects.
    Burres SA; Crayton JW; Gomez CM; Richman DP
    Ann Neurol; 1981 Jun; 9(6):563-8. PubMed ID: 6167199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of acetylcholine receptor antibodies in myasthenia gravis.
    Appel SH; Elias SB; Chauvin P
    Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive transfer of seronegative myasthenia gravis to mice.
    Burges J; Vincent A; Molenaar PC; Newsom-Davis J; Peers C; Wray D
    Muscle Nerve; 1994 Dec; 17(12):1393-400. PubMed ID: 7969240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholine release in diaphragm of rats with chronic experimental autoimmune myasthenia gravis.
    Kelly JJ; Lambert EH; Lennon VA
    Ann Neurol; 1978 Jul; 4(1):67-72. PubMed ID: 211931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to experimental autoimmune myasthenia gravis in genetically inbred rats. Association with decreased amounts of in situ acetylcholine receptor-antibody complexes.
    Biesecker G; Koffler D
    J Immunol; 1988 May; 140(10):3406-10. PubMed ID: 3258882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-fiber electromyography in experimental autoimmune myasthenia gravis.
    Verschuuren JJ; Spaans F; De Baets MH
    Muscle Nerve; 1990 Jun; 13(6):485-92. PubMed ID: 2366822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.
    Tzartos SJ
    In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR
    Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-acetylcholine receptor antibodies induced in mice by syngeneic receptor without adjuvants.
    Scadding GK; Calder L; Vincent A; Prior C; Wray D; Newsom-Davis J
    Immunology; 1986 May; 58(1):151-5. PubMed ID: 3486818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
    Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
    J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.